chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial VAERS filed Feb 2003. This 33 year old received her first three ANTHRAX vaccination 02 Nov 1998, 12 Nov 1998, & 28 Nov 1998. AVA #4 and #5 were administered 15 Dec 1998 and 02 Aug 1999. She remembers the injection sites burning then sore with a nodule for approximately one week with full resolution of symptoms. This SM advised late (Nov/Dec?) 1999-early 2000 she experienced a small fine red macular itchy rash to right side of chest under her bra line that resolved with 1-2 days of TRIAMCINOLONE. (No wire in bra.) This rash was attributed to irritation due to fabric softeners. She was transferred to another state in March/April 2000. On 17 July 2000 she reported to ER with a 2 week history of a reoccurring itchy maculopapular rash to "bilateral extensor surfaces of forearms and medial thighs". She was diagnosed with contact dermatitis and advised to discontinue fabric softeners. Rash continues as of 2009 with reflare after 11/12/2008 IM Flu and Yellow fever vaccinations.
Tenderness at injection site and a hard spot about the size of a quarter; High Fever and chills within first twelve hours then sinus conjestion for about 1week.
Reports flu like symptoms following each anthrax vaccine - diarrhea, nausea and vomiting, generalized body aches, fever, and chills ; also experienced sinus congestion, post-nasal discharge, and sore throat. He usually woke up with above symptoms the morning following receipt of the anthrax vaccines ; the symptoms seem to peak around day 3 or 4, and resolved by day 6-7. Reports diarrhea the whole time he was in Iraq until present. In 10/04, experiencing changes in his visual perception. Describes these episodes "like eyes going back and forth" but if he were to look in mirror, his eyes would not be moving. The visual changes are worse with head movements and usually only last seconds. In 10/04, began experiencing polyarthralgias. He describes the sensation as aching, like with the flu or "like a toothache". All joints are affected and usually ache all at the same time. The joints that ache the most are his elbows, knees, and hands. He has had 2 episodes of his right elbow becoming edematous, erythematous, and warm; his movement was limited due to pain. Experienced joint pain and swelling of his fingers, but no redness or warmth of affected joints; this continues to occur 1-2 times per week; he says his hands turn white during these episodes and he experiences associated joint stiffness. Rheumatology evaluation was negative for inflammatory joint disease. Around 10/04, began experiencing chronic headaches. Headache pain is located at base of neck and described as sharp, throbbing pain. Typically awakens with pain and headaches usually last about 3 hours. Rates level of pain intensity as a level 7. Headaches occur almost every morning. OTC medications like Aleve provide relief. While deployed in 03/05, experienced sensation of dizziness. Besides the feeling of dizziness, he feels unsteady, like he is ready to fall over. He describes this sensation as imbalance or feeling like he is going to faint. The sensation usually comes on gradually and lasts 1-2 days. Episodes occur about every 3 weeks. Movement and position changes seem to precipitate and aggravate senstion. He says when he turns his head and looks in one direction, his body sways that way. When dizzy, he also notes the onset of altered sensation/paresthesias affecting his teeth, tongue and digits. He also describes the sensation of feeling like water is dripping down the side of my face. Has noted feeling cold, but experiencing sweats during episodes of dizziness. Denies black outs or fainting. Denies rapid respirations or hyperventilation prior to onset of intermittent, bilateral tinnitus over the last year, usually lasting a few seconds. Tinnitus does not interfere with activities of daily living, but is sometimes distracting and makes concentration difficult. During his deployment, began experiencing intermittent, brief episodes of palpitations with sensation of heart beating out of my chest. Counted his pulse during a few episodes and his pulse was over 100 (tachycardia). When he was able to seek medical attention, elevated blood pressure measurements were noted. Some of episodes were associated with dizziness. No previous history of blood pressure elevation prior to deployment.
Acute pericarditis; Soreness on the left shoulder (injection site); A spontaneous report was received from a consumer who was also a 75-years-old, male patient, who received Moderna's COVID-19 Vaccine (mRNA-1273) and who experienced soreness on the left shoulder (injection site)/ injection site soreness and acute pericarditis/ pericarditis.  The patient's medical history was not provided. Concomitant medications were not reported.  On 16 Jan 2021, seven days prior to onset of the events, the patient received their first two planned doses of mRNA-1273 (Batch number: 039K20A) intramuscularly for the prophylaxis of COVID-19 infection.  On 23 Jan 2021, the patient experienced soreness on the left shoulder (injection site), tiredness, headache, and chest pain.   On 02 Feb 2021, he had difficulty breathing even with his continuous positive airway pressure (CPAP) machine and called 911. He was taken to emergency room (ER) and was diagnosed with acute pericarditis.  Treatment included ibuprofen, pantoprazole, and colchicine.  Action taken with mRNA-1273 in response to the events was not reported.  The outcome of events, soreness on the left shoulder (injection site and acute pericarditis, was not reported.; Reporter's Comments: This case concerns a 75 year old male subject, who experienced a serious unexpected event of Pericarditis and a non-serious expected event of injection site pain after first dose of mRNA1273 (Lot# 039K20A). Very limited information has been provided regarding the event of pericarditis at this time. Further information has been requested.
p/vax pt exp muscle/joint soreness upper back/shoulders; flu like sx; diminished appetite; extreme fatigue, T103; h/a; papules on hands; soles of feet, toes, mouth&throat;dx:erythema multiforme; tx:cortisone & H-1 blocker
PT states she received Covid-19 booster (3rd dose) around 10/31/2021, and experienced swollen, tender lymph nodes. PT states this resolved 11/7/2021. Unknown manufacturer and lot number.
This case was reported by a physician and described the occurrence of fever in a 6-month-old male subject who was vaccinated with PEDIARIX (GlaxoSmithKline), TETRACOQ and pneumococcal vaccines (non-GSK). There were no concurrent medications. The subject had no relevant medical history or any adverse events following previous vaccinations. On 8 June 2007 at 15:00 the subject received 3rd dose of PEDIARIX (.5 ml, unknown), the 3rd dose of TETRACOQ and the 3rd dose of Pneumococcal vaccine. On 8 June 2007, less than one day after vaccination with PEDIARIX, TETRACOQ and Pneumococcal vaccine, the subject experienced fever and chills. The physician reported that per the subject's father, the infant experienced fever and chills on the same day he was vaccinated with PEDIARIX back in 2007. The infant had to be treated in the emergency room for these events. The treatment required was not known by the reporting physician. The reporting physician did not know which vaccine may have caused the events as the child was concurrently vaccinated with TETRACOQ and pneumococcal vaccine on the same day as PEDIARIX. The reporting physician was considering whether to continue the child's vaccination series DTAP. The child is currently two years old. The events resolved on an unspecified date.
Shot 12/7/09 woke up with weakness, fever, chills, sweating, dizziness and nausea.
Flaccidity, unresponsive after Imm. responded to ammonia to nares. Awakened teary and disoriented. Placed in supine position with knees bent. A/O, identifying relatives and DOB. Returned to pre Imm. mental status. AMB. Without sequelae. BP 10:35AM 118/60 and 10:15AM 110/70. Warm dry skin-pale in color.
p/vax found to have 4.3cm medial non tender mass of lt thigh;
Patient received DTaP, IPV, MMR on 4/7/03. Left thigh began to swell on 4/9/03. + erythema, + warmth, - fever. No limp or pain. - rash. Swelling appears left upper thigh and spreading down to knee.
Patient experienced tingling on lips and back of the tongue as well as coughing. Then benadryl was administered which led to resolution.
Nausea, diarrhea, temp 100.5, Swelling to right arm, pain, huge welp, redness, itchiness, not responding to antihistamine and anti inflammatory
Nervous before shots, mom held her hand. Fine after first shot. Immediately felt hot, clammy, sweaty, also was unresponsive for 20-30 seconds. Called 911. EMT took BP 2 x and it improved by 2nd reading (103/70). Patient declined to go to hospital. Felt and looked better. Walked out under own power at 450pm.
11/03/22 presents to ED for "hyperglycemia with AMS" "fever and sore throat". PMHx of " DM, HTN, HLD, hypothyroidism, Autoimmune Hepatitis"
pt recvd vax; induration, erythema & warmth at site of inject; cellulitis;
PER MOM,"BRIGHT RED WELT" QUARTER SIZED ON AREA WHERE VARICELLA VACINE GIVEN; FACE AND BOTTOM ALSO "FLUSHED". 10/11/09 - PIMPLE LIKE AREAS ERUPTED ON BODY, BUT PER DAD, GONE TODAY 10/12/09
Blood in urine; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD URINE PRESENT (Blood in urine) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001A21A) for COVID-19 vaccination.     Concomitant products included BOTULINUM TOXIN TYPE A (BOTOX) and OXYCODONE HYDROCHLORIDE, OXYCODONE TEREPHTHALATE, PARACETAMOL (PERCOCET [OXYCODONE HYDROCHLORIDE;OXYCODONE TEREPHTHALATE;PARACETAMOL]) for an unknown indication.    On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Feb-2021, the patient experienced BLOOD URINE PRESENT (Blood in urine). On 03-Mar-2021, BLOOD URINE PRESENT (Blood in urine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment included as Percocet.
had their 1st dose of the Moderna Covid-19 Vaccine on 27May2021 but has not had the 2nd dose/2nd dose not received; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (had their 1st dose of the Moderna Covid-19 Vaccine on 27May2021 but has not had the 2nd dose/2nd dose not received) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066D21A) for COVID-19 vaccination.     Concurrent medical conditions included Chronic pain. Concomitant products included OXYCODONE and GABAPENTIN for Pain.    On 27-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Aug-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (had their 1st dose of the Moderna Covid-19 Vaccine on 27May2021 but has not had the 2nd dose/2nd dose not received). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (had their 1st dose of the Moderna Covid-19 Vaccine on 27May2021 but has not had the 2nd dose/2nd dose not received) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (had their 1st dose of the Moderna Covid-19 Vaccine on 27May2021 but has not had the 2nd dose/2nd dose not received) to be possibly related.    Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: Follow up received on 5-AUG-2021. Added patient demographics, medical history, suspect drug details, concomitant medication, event details and causality.
approx 2hr post vax pt became lethargic would not feed well;seen in Er pt took nap/slept through eval;recovered fully 24hr post vax;
10/18/18 red area left arm. 10/19/18 Localized cellulitis left arm, hot and red. KEFLEX ordered. Area larger than previous day. Continued to monitor. On 10/20/18 less inflamed. Continue to monitor. 10/22/18 no erythema at site of pneumonia vaccine. Continue KEFLEX. 10/25/18 cellulitis of left arm resolved.
Patient presented to emergency department on 9/18/2021 with a sore throat and dry cough. He was found to be COVID-19 positive and was admitted for further management. Patient was treated with dexamethasone. He was discharged home on 9/26/2021.
high fever - 102 F; very swollen and painful lymph nodes in left armpit and right but not as bad sweaty feet; very swollen and painful lymph nodes in left armpit and right but not as bad sweaty feet; very swollen and painful lymph nodes in left armpit and right but not as bad sweaty feet; abnormal horrific headache; This is a spontaneous report from a contactable consumer (patient). A 40-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EW0179 and expiration date was not reported), via an unspecified route of administration in left arm, on 17May2021 at 14:30 (at the age of 40 years old) as second dose, single for COVID-19 immunization in a Public Health Clinic/Veterans Administration facility. The patient's medical history was not reported. The patient previously took prochlorperazine maleate (COMPAZINE) and experienced drug allergy. Concomitant medications included esomeprazole sodium (NEXIUM) and celecoxib (CELEXA). Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EW0172 and expiration date was not reported), via an unspecified route of administration in left arm, on Apr2021 at 10:30 (at the age of 40 years old) as first dose, single for COVID-19 immunization. The patient was not pregnant at the time of vaccination and did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, it was unknown if the patient diagnosed with COVID-19 and post-vaccination, the patient was tested for COVID-19 with nasal swab and the result was negative on 16Apr2021. The patient experienced high fever with a temperature of 102 F, very swollen and painful lymph nodes in left armpit and right but not as bad sweaty feet and abnormal horrific headache on 17May2021 at 14:30. This case was considered as non-serious and no treatment was given to the patient for these events. The outcome of these events was recovering at the time of report.
Patient laid in bed all day after second dose; more fatigue after his second dose; This spontaneous case was reported by a consumer and describes the occurrence of BED REST (Patient laid in bed all day after second dose) and FATIGUE (more fatigue after his second dose) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004D21A and 009D21A) for COVID-19 vaccination.  No Medical History information was reported.  On 24-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 24-Jul-2021, the patient experienced BED REST (Patient laid in bed all day after second dose) and FATIGUE (more fatigue after his second dose). On 25-Jul-2021, BED REST (Patient laid in bed all day after second dose) and FATIGUE (more fatigue after his second dose) had resolved.     No concomitant medications were reported. Treatment information was not provided.  This case was linked to MOD-2021-406415 (Patient Link).
chills, fever, sweating, migraine, nausea  - lasted  2 days; migraine 3 days.
ache; headache; nausea; tiredness; injection site hot; injection site redness; injection site swell; A spontaneous report was received from a consumer concerning a female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and developed injection site hot, injection site redness, injection site swell, headache, ache, nausea and tiredness.  The patient's medical history was not provided. No relevant concomitant medications were reported.  The patient received their first of two planned doses of mRNA-1273 on 05 Jan 2021 intramuscularly for prophylaxis of COVID-19 infection. The patient received their second of two planned doses of mRNA-1273 on 02 Feb 2021 intramuscularly for prophylaxis of COVID-19 infection.   Patient had a question on an adverse effect they had and wanted some information. She mentioned that she took her fist dose on 05 Jan 2021 and experienced injection hot, redness and swell. Second dose was on 02 Feb 2021, she experienced, headache, ache, nausea and tiredness. She mentioned that she followed up with her doctor. No further information provided.  No treatment information was provided for events.  Action taken with RNA-1273 in response to the event was unknown.  The outcome of the events was unknown.  The reporter did not provide an assessment for the events, injection site hot, injection site redness, injection site swell, headache, ache, nausea and tiredness.
Immediately after reaction both inoculation areas to both thighs became indurated swollen and erythematous. Erythema 4-4.5 cm on both sides with central induration of 2.0 cm on both sides. After 15 minutes the induration resolved. After one hour the erythema completely resolved.
Patient presented symptoms of high blood pressure three days after receiving the vaccine (05/31/21). Seven days later, the wife tells the pharmacy that she has a headache in the left back, has a droopy eyelid on the left side and numbness in the left area of ??the face. He was advised to visit his doctor, and his wife indicated that the patient was going to go that same day (04/06/2021).
Information has been received from a physician concerning a 30-month old white female w/ NKDA  and no past medical history who on 01/05/01 was vaccinated with a first dose in the left tricep with varicella  virus vaccine live. Concomitant medications that day included a third dose of in the right tricep of poliovirus vaccine. There was no illness at the time of vaccination. On 07/04/01, the patient developed shingles of the left arm and hand spreading from the shoulder to the fingers. The zoster  was described as a shingle left arm dermatome herpes zoster with multiple vesicles. The patient was otherwise asymptomatic. She was treated with acyclovir. there was no post vaccination rash within 42 days of injection and the child has no history of chicken pox or herpes zoster exposure. The child does not attend day care a vesicular specimen was sent  for analysis. It was noted that a "varicella stain" came back positive and a "DFA' and culture" from the lab was positive as well. A specimen has been sent to a university for VZV analysis. Unspecified medical attention was sought.  Follow up information has been received from a health professional who reports the specimen was VZV (+) and the presence of VZV strain was identified. At the time of this report the patient still had active herpes zoster The vesicles resolved by 07/24/01, but the child was still experiencing pain. Additional information has been requested.
hours after administration, patient experienced dizziness / vertigo. She felt like her eyes were in a haze / cloudy. there was muscle tensions through the legs (not arms)
Pt reported general weakness and headache at 1120. Vitals were 136/90 bp, 90 hr, and 97% O2 room air. Pt reported no itchiness or hives. Pt  stated not eating much in the morning. Pt given water and orange juice . Pt advised to stay for further observation. Vitals reassessed at 1146. BP 142/96, 87 hr, and  97% O2  room air. Patient stated his headache was gone and he felt itchiness in left and right arms.  At approx. 1150, patient given diphenhydramine oral solution 50 mg. Patient advised to stay for 30 minutes. Patient declined and stated he wanted to leave. Patient  ordered a ride and left facility with steady gait and unlabored breathing at approx.  1200.
From 12 hours after dose, pt developed myalgias, nausea, vomiting, disseminated vesicular rash from knees to neck that persisted until clinic visit 84 hours post dose. Treatment with oral steroids.
Place where vaccine was injected turned red, a little swollen and itchy. It disappeared in about a week and a half.
Severe shoulder pain. Could not lift arm above head. Pain continued the next day followed by slight fever, swelling of ejection area, with blotchy hives. Hot to the touch. Pain and swelling starting to diminish 3 days after injection.
Hospital Course:    Patient is a 90 y.o. male patient of DO with a history of mild dementia but living independently presented to Hospital 12/05/2022 with chest discomfort radiating to both arms.  His symptoms had begun the day before but were less specific.  He was found to have ST elevation, albeit with Q waves across the anterior precordium.  Due to ongoing symptomatology he was taken to the cardiac catheterization lab where he underwent intervention to the LAD successfully.   He continues to have issues with sundowning, but now is in sinus rhythm and his renal function has normalized.  He was then discharged home 12/10/2022 with home health assistance.  He will also follow-up with cardiology.    Discharge Diagnoses:   Anterior STEMI Risk factors: HLD, CKD, Heart Score: 8. Presented with chest pain of unclear duration -Troponin 2,501, EKG with ST elevations V4/5/6, LHC mid/distal LAD showing complete occlusion Timi flow 0 -- > timi 3 flow after intervention.  -Continue eliquis, plavix, atorvistatin, lisinopril 5 mg    Paroxsymal A Fib. With RVR Likely in the setting of recent MI and volume depleted status -Received Lopressor IV 2.5 x 4 overnight with improvement of HR -transition from amio gtt to oral amio 200 mg BID, after risks and benefits discussion with family, will transition to 2.5mg of eliquis twice daily  -We will arrange follow-up with cardiology as outpatient locally,    Aspiration Pneumonitis In the setting of emesis, with potential chronic contributions -leukocytosis, with CXR changes per above -Transition to augmentin for 5 days therapy total, SLP consulted for swallow minor aspiration with strong cough reflex recommend pureed diet.    Urinary Retention Unclear etiology, possibly underlying chronic retention exacerbated by poor intake -Foley removed 12/09 -Plan: Will encourage patient to spontaneously void on his own, may require further workup if not -patient will f/u with known urologist, Dr.     CKD IV Baseline Cr 1.8-2.0, not on iHD -Cr at baseline -Continue to monitor   Acute Hypoxemic Respiratory Failure, improving In the setting of an aspiration event. -CXR showing retrocardiac opacities consistent with aspiration -continue supplemental O2 wean with goal sat >88%. Patient may need homegoing O2 Anemia Likely associated with CKD, cannot rule out mineral or vitamin def playing a role. -Hgb 11.2, Iron panel showing iron def, b12/folate wnl -Continue ferrous sulfate 325 mg EOD, Continue to monitor transfuse hgb<7      Abnormal CXR Etiology unclear, primary concern would be potential underlying malginancy -Non-emergent CT chest recommended, however patient transitioned to DNR-CC   GOC Due to continuing decline.  -Palliative care consulted for GOC and EOL discussion. Transitioned to DNR-CC. Patient does not qualify for hospice at this time -Patient will require a hospital bed after evaluation in the hospital
On 09/28/2022 in the evening  I had slight headaches and runny nose.  I  did a COVID-19 home test which was positive. My symptoms were very mild .  On 09/29/2022 I called my doctor who prescribed me  Steroids' for 5 days. I felt better within 4 days.  I tested positive for 12 days. On 10/12/2022 I tested negative.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No information on patient's medical history, drug reactions or allergies were provided. On 27-APR-2015, the patient was subcutaneously vaccinated with 0.65 ml dose of improperly stored ZOSTAVAX lot # K020801, expiration date 31-JAN-2016, in the right arm. No adverse effects were reported. Additional information has been requested.